Document is current
Any future updates will be listed below
-
Authors
Fibriansah, Guntur https://orcid.org/0000-0002-9990-3335
Ng, Thiam-Seng https://orcid.org/0000-0002-1668-8976
Lim, Xin-Ni https://orcid.org/0000-0001-8117-3613
Shebanova, Anastasia
Ng, Lee Ching https://orcid.org/0000-0003-2413-3863
Tan, Song Ling
Tan, Aaron W. K. https://orcid.org/0000-0002-4046-7380
Shi, Jian
Crowe, James E. Jr. https://orcid.org/0000-0002-0049-1079
Lok, Shee-Mei https://orcid.org/0000-0003-4631-8041
-
Funding
Funding for this research was provided by:
Ministry of Health -Singapore (Duke-NUS Signature Research Programme)
Ministry of Education—Singapore (MOET32023-0002)
- License Information
-
More Information
Article History
Received: 10 August 2023
Accepted: 9 September 2025
First Online: 16 October 2025
Competing interests
: J.E.C. has served as a consultant for Luna Labs USA, Merck Sharp & Dohme Corporation, Emergent Biosolutions, GlaxoSmithKline and BTG International Inc., is a member of the Scientific Advisory Board of Meissa Vaccines, a former member of the Scientific Advisory Board of Gigagen (Grifols) and is founder of IDBiologics. The laboratory of J.E.C. received sponsored research agreements from AstraZeneca, Takeda, and IDBiologics during the conduct of the study. Vanderbilt University has applied for patents related to some of the antibodies described in this paper. The remaining authors declare no competing interests. There are restrictions to the availability of the human monoclonal antibodies DENV-290 and DENV-115 because the two antibodies are patented: WO 2021/154530 A1, contact J.E.C. (james.crowe@vumc.org) for further information.
